logo
Improved breast screening could detect extra 3,500 cancers a year in UK

Improved breast screening could detect extra 3,500 cancers a year in UK

Rhyl Journal21-05-2025

A new trial found extra scans for some women can pick up early-stage cancers that remain 'hidden' during regular mammograms – more than trebling cancer detection.
Researchers from the University of Cambridge are now calling for additional scans to be added to breast screening programmes for the group of women who have very dense breasts.
Around 10% of women have very dense breasts, which means they have more fibrous and glandular tissue and less fatty tissue than other women.
Those with dense breasts are already known to face a fourfold increased risk of breast cancer compared to women without.
The new trial, published in the Lancet medical journal, was carried out on 9,361 women across the UK who have dense breasts and had a negative (no cancer) mammogram result.
During the trial, which looked at additional scanning methods, an extra 85 cancers were found.
The two methods examined were contrast enhanced mammography (CEM), where dye is used to make blood vessels more visible, and abbreviated magnetic resonance imaging (AB-MRI), which is faster than a regular MRI.
The experts calculated that adding either of these methods to existing breast screening could detect 3,500 more cancers per year in the UK.
And because screening reduces death for about 20% of cancers detected, this could mean an extra 700 lives saved each year, they said.
A third scanning method used in the trial – automated whole breast ultrasound (ABUS) – also picked up cancers but was much less effective than CEM and AB-MRI.
Overall, per 1,000 women scanned, CEM detected 19 cancers, while AB-MRI found 17 and ABUS found four.
With mammograms already detecting around eight cancers per 1,000 women with dense breasts, additional scans could therefore more than treble breast cancer detection.
At the moment, because denser breasts look whiter on mammograms, the usual mammogram scan cannot pick up all these cancers.
Early-stage cancers also appear white, meaning they are difficult to distinguish.
Professor Fiona Gilbert, from the University of Cambridge and honorary consultant radiologist at Addenbrooke's Hospital, led the study.
She said: 'Getting a cancer diagnosis early makes a huge difference for patients in terms of their treatment and outlook.
'We need to change our national screening programme so we can make sure more cancers are diagnosed early, giving many more women a much better chance of survival.'
In the study, the researchers concluded: 'Abbreviated MRI and contrast-enhanced mammography detected three times as many invasive cancers compared with ABUS, with cancers being half the size.
'This study shows that supplemental imaging could lead to earlier detection of cancer in women with dense breasts.'
The trial was funded by Cancer Research UK with support from the National Institute for Health and Care Research Cambridge Biomedical Research Centre.
Professor Stephen Duffy, from Queen Mary University, London, the trial statistician and a screening programme expert, said: 'The NHS breast screening programme has made a huge difference to many lives.
'Thanks to these results, we can see that the technology exists to make screening even better, particularly for the 10% of women with dense breast tissue.'
Dr David Crosby, head of prevention and early detection at Cancer Research UK, said: 'This study shows that making blood vessels more visible during mammograms could make it much easier for doctors to spot signs of cancer in women with dense breasts.
'More research is needed to fully understand the effectiveness of these techniques, but these results are encouraging.'
At the moment, the UK National Screening Committee does not recommend any additional imaging for women with dense breasts who have a negative result on a mammogram.
Dr Kotryna Temcinaite, head of research communications and engagement at Breast Cancer Now, said: 'The UK National Screening Committee now needs to consider this research as part of their current review to determine whether women with very dense breasts should be offered additional imaging during their routine screening.
'If the UK National Screening Committee recommends additional imaging for screening women with very dense breasts, we'll push for those changes to be rolled out as quickly as possible across the UK.
'Routine breast screening is the most likely route to finding breast cancer early, when treatment is most likely to be successful.
'While we know that the current process can be less effective in detecting cancers in dense breasts, we still encourage all women to attend mammogram screening when invited.'
Addenbrooke's patient Louise Duffield was one of 85 women diagnosed with cancer thanks to the additional scans used in the trial.
Aged 60, the grandmother of four from Ely, Cambridgeshire, had an AB-MRI scan which identified a small lump deep inside one of her breasts.
She said: 'When they rang to say they'd found something, it was a big shock.
'You start thinking all sorts of things but, in the end, I just thought, 'at least if they've found something, they've found it early'. The staff were brilliant, and so supportive.'
A Department for Health and Social Care spokesperson said: 'Research is being conducted into the use of additional tests for women with dense breasts, as part of the NHS breast screening programme.
'The UK National Screening Committee is reviewing this evidence as it becomes available.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

What we know about the new NHS cervical screening guidelines
What we know about the new NHS cervical screening guidelines

The Independent

time3 hours ago

  • The Independent

What we know about the new NHS cervical screening guidelines

New NHS guidelines in England will invite women aged 25-49 with negative HPV tests to cervical screenings every five years instead of every three, starting next month. The change follows recommendations from the UK National Screening Committee and aligns England's screening intervals with those of Wales and Scotland. Analysis from King's College London indicates that extending the screening interval to five years for HPV-negative women maintains a similar rate of cancer detection as the current three-year interval. Health Minister Ashley Dalton stated the change aims to increase testing opportunities for women with HPV while extending screening intervals for those with negative tests, emphasising early detection and treatment. Experts encourage women to attend screenings when invited, with the NHS implementing measures like phone reminders to improve participation, while Cancer Research UK highlights the impact of screening and HPV vaccination on reducing cervical cancer rates.

Warning over 'real and frightening risk' of period tracker apps
Warning over 'real and frightening risk' of period tracker apps

Wales Online

time3 hours ago

  • Wales Online

Warning over 'real and frightening risk' of period tracker apps

Warning over 'real and frightening risk' of period tracker apps Three apps alone have been downloaded 250million times These apps can collect information on exercise, diet, medication, sexual preferences, hormone levels and contraception use Women face 'real and frightening privacy and safety risks' when using period tracker apps, experts have warned. Academics from the University of Cambridge said that personal information in the app can be collected and 'sold at scale'. A new report from experts at Cambridge's Minderoo Centre for Technology and Democracy said that this 'poses risks and harms for users'. Researchers said that menstrual data can provide insights into people's health and their reproductive choices. ‌ These apps can collect information on exercise, diet, medication, sexual preferences, hormone levels and contraception use, they added. This information can be a 'gold mine' for consumer profiling, the authors of the new report said. ‌ Many women who download the apps do so when they are trying to get pregnant, which the authors point out leads to a dramatic shift in shopping behaviour. 'Data on who is pregnant, and who wants to be, has therefore emerged as some of the most sought-after information in digital advertising,' they said. The point out how period tracking apps have rapidly risen in popularity, with global downloads of the three most popular apps surpassing 250 million. 'Cycle tracking apps (CTA) are a lucrative business because they provide the companies behind the apps with access to extremely valuable and fine-grained user data,' the experts wrote in their new report. Article continues below 'CTA data is not only commercially valuable and shared with an inextricable net if third parties (thereby making intimate user information exploitable for targeted advertising), but it also poses severe security risks for users.' They point out that in the wrong hands, the data collected by the apps could result in health insurance 'discrimination'; risks to job prospects or even domestic abuse. The research team called for better governance of the 'femtech' industry, including improved data security of these apps and for them to introduce 'meaningful consent options'. They also called for public health bodies to launch alternatives to commercial tracking apps. 'Menstrual cycle tracking apps are presented as empowering women and addressing the gender health gap,' said Dr Stefanie Felsberger, lead author of the report. Article continues below 'Yet the business model behind their services rests on commercial use, selling user data and insights to third parties for profit.' 'There are real and frightening privacy and safety risks to women as a result of the commodification of the data collected by cycle tracking app companies.' Professor Gina Neff, executive director of Cambridge's Minderoo Centre, added: 'The use of cycle tracking apps is at an all-time high. Women deserve better than to have their menstrual tracking data treated as consumer data, but there is a different possible future.'

The therapy that could help prevent food-related liver cancer
The therapy that could help prevent food-related liver cancer

The Independent

time4 hours ago

  • The Independent

The therapy that could help prevent food-related liver cancer

New research has identified a pathway involving the genes p53 and TIGAR that may prevent fatty liver disease from progressing to liver cancer, a condition for which there are currently no effective treatments. Researchers from Glasgow Caledonian University, the Cancer Research UK Scotland Institute, and The Francis Crick Institute discovered that p53 protects the liver from high-fat, high-sugar diets through the gene TIGAR, which acts as an antioxidant and detoxifies lipids in a fatty liver. The breakthrough suggests that antioxidant therapy could be developed to mimic the protective response of p53 and TIGAR, potentially preventing the development of key features of fatty liver disease. Dr. Timothy Humpton noted that the research establishes a key role for p53 and TIGAR in protecting against the progression from liver disease to liver cancer, suggesting that targeting this pathway through antioxidants is of great interest for future therapies. He also highlighted that fatty liver disease, often caused by poor diet and lack of exercise, is hard to diagnose due to its asymptomatic nature.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store